Policy
Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
What do you wish someone would’ve told you at the beginning of your career? Most people reflect on their career development and think, ‘If only I knew then what I know now, I’d be farther along.’
A prostate cancer drug jointly developed by healthcare giant Bayer and Finland-based Orion can slow the spread of the disease, according to late-stage study results announced early Wednesday.
The FDA, as well as other government agencies, have expressed alarm at the rate of opioid-related overdoses in the United States – an issue that has become an epidemic across the heartland.
Abdul Rahman bin Mohammed Al Owais, UAE Minister of Health and Prevention, signed a partnership agreement with Leif Johansson, Chairman of leading global pharmaceutical company AstraZeneca, as part of its strategy to enhance the outcomes of national indicators in the field of respiratory diseases and cancer, to achieve the objectives of the National Agenda 2021.
Smart services to be showcased include electronic sick leave attestation, online permits for imported drugs, ‘Sanad &Rahma’ & electronic birth and death certificates
The American University Washington College of Law and the Food and Drug Law Institute hosted a conference late last week. One of the highlights was a plenary session that featured former commissioners of the U.S. Food and Drug Administration (FDA).
The FDA approved Sanofi and Regeneron’s Dupixent (dupilumab) as an add-on maintenance therapy for patients with moderate-to-severe asthma. The approved group is age 12 years and older with either an eosinophilic phenotype or with an oral corticosteroid-dependent asthma.
Regeneus Ltd is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.
Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)
Quark Venture Inc. has petitioned the British Columbia Supreme Court to overturn an unfavourable arbitration award concerning its decision to deny further investment to MSI Methylation Sciences, Inc. (“MSI”).